Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 years or older~* angiopathic or angioneuropathic critical limb ischemia (at least Wagner-Armstrong stadium II)~* participation in the August-1 Register~* revascularization not possible or residual ischemia after revascularization~* persisting ulcerations despite antibiosis, adjustment of blood glucose levels and debridement~* expected further hospitalization for at least 3 weeks (pressure relief and antibiosis)~* fibrinogen \>= 4g/l~* signed informed consent~Exclusion Criteria:~* life expectancy \< 1 year~* prior major amputation~* planned major amputation~* prior therapy of the current episode of diabetic foot syndrome with urokinase (except in cases of revascularization when the duration between the intervention and randomization must not exceed 7 days)~* mechanical heart valve substitute~* cerebral event with CT-detectable changes in the last 3 months~* non-remediated proliferation retinopathy~* uncontrolled hypertension (systolic \>180 mmg, diastolic \>100 mmHg)~* hemorrhagic diathesis (spontaneous quick \< 50%, spontaneous PTT \> 40 s, thrombocytes \< 100 Gpt/l)~* gastrointestinal bleeding or ulcers in the last 4 weeks~* prior reverse bypass operation~* contraindications against therapy with urokinase acc. to the SMPc~* concurrent participation in another clinical trial~* insufficient compliance~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard therapy (Type: NO_INTERVENTION): patients receiving standard therapy for diabetic foot syndrome with critical limb ischemia, i. e. structured therapy of lesions with antibiosis, pressure relief and therapy of risk factors according to the relevant guidelines.
- urokinase (Type: ACTIVE_COMPARATOR): patients receiving urokinase short infusions in addition to standard therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).